Current Pharmaceutical Design

William A. Banks  
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA

Back

Inhibitors of HIV-1 Entry

Author(s): Ewa D. Micewicz and Piotr Ruchala

Affiliation: Department of Medicine, Room 37-055 Center for Health Sciences, 10833 LeConte Avenue, Los Angeles, CA 90095.

Keywords: Antivirals, fusion inhibitors, entry inhibitors, peptides, HIV

Abstract:

Since the discovery of human immunodeficiency virus (HIV) as a causative agent of acquired immune deficiency syndrome (AIDS) various strategies were employed to counter its devastating actions. One such concept relies on the prevention of HIV entry into host’s “competent” cells by means of compounds known as entry inhibitors. HIV entry inhibitors comprise a group of immensely diverse compounds ranging from proteins/antibodies to small organic molecules and capable of targeting various stages of viral entry. Although already in clinical use, this approach to HIV therapy is still being investigated to produce new promising antiviral compounds. Here, we review the latest advances in this area.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 19
ISSUE: 10
Page: [1784 - 1799]
Pages: 16
DOI: 10.2174/1381612811319100003